{"id":772,"date":"2021-06-30T10:30:30","date_gmt":"2021-06-30T10:30:30","guid":{"rendered":"https:\/\/abolongroup.com\/?post_type=abolon-transactions&#038;p=772"},"modified":"2024-08-07T10:31:42","modified_gmt":"2024-08-07T10:31:42","slug":"abolon-advises-medipart-on-the-sale-of-a-majority-stake-in-actiol-gmbh-an-innovator-in-ophthalmic-biomaterials","status":"publish","type":"abolon-transactions","link":"https:\/\/abolongroup.com\/de\/abolon-transactions\/abolon-advises-medipart-on-the-sale-of-a-majority-stake-in-actiol-gmbh-an-innovator-in-ophthalmic-biomaterials\/","title":{"rendered":"Abolon advises Medipart on the sale of a majority stake in Actiol GmbH, an innovator in ophthalmic biomaterials"},"content":{"rendered":"<p>Abolon has been the exclusive adviser to Medipart AG, Switzerland, (&#8220;Medipart&#8221;) on the sale of its majority stake in the share capital of Actiol GmbH (&#8220;Actiol&#8221; or the &#8220;Company&#8221;) to an international investor group. The transaction has been closed end of June 2021. The transaction value has been agreed to be kept confidential.<\/p>\n<p>Actiol is a stock corporation with registered office in Am\u00f6neburg, Germany. The Company is active in development and manufacturing of ophthalmic biomaterials, particularly acrylic IOL polymers.<\/p>\n","protected":false},"template":"","class_list":["post-772","abolon-transactions","type-abolon-transactions","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/abolongroup.com\/de\/wp-json\/wp\/v2\/abolon-transactions\/772","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/abolongroup.com\/de\/wp-json\/wp\/v2\/abolon-transactions"}],"about":[{"href":"https:\/\/abolongroup.com\/de\/wp-json\/wp\/v2\/types\/abolon-transactions"}],"wp:attachment":[{"href":"https:\/\/abolongroup.com\/de\/wp-json\/wp\/v2\/media?parent=772"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}